erlotinib

Known as: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine 
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Lung cancer is the foremost cause of cancer-related deaths world-wide. Both, the major forms of lung cancer, Non-small cell lung… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is usually limited to four to six cycles… (More)
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • table 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE To evaluate the effect of KRAS and epidermal growth factor receptor (EGFR) genotype on the response to erlotinib… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Epidermal growth factor receptor (EGFR) mutations have been associated with tumor response to treatment with single-agent… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor. This phase II… (More)
Is this relevant?